De JUPITER-studie

In the recent ‘Justification for the Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin’ (JUPITER) study rosuvastatin was shown to decrease the risk of vascular events in people at low risk, i.e. with non-elevated cholesterol levels. This is understandable from the perspective that even people with low or ‘normal’ cholesterol levels have a certain risk of cardiovascular disease. This does not imply that low-risk people should be prescribed statins.